Last reviewed · How we verify

NCT06185816

Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain

Not yet recruiting Phase 2, PHASE3 Last updated 29 December 2023
What this trial tests

Phase 2, PHASE3 trial testing Active Treatment in Pain, Nerve in 95 participants. Not yet recruiting.

Timeline
1 January 2024
Primary endpoint
1 January 2028
1 January 2029

Quick facts

Lead sponsorStanford University
PhasePhase 2, PHASE3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingsingle
Primary purposetreatment
Enrollment95
Start date1 January 2024
Primary completion1 January 2028
Estimated completion1 January 2029

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

18 and older, any sex, with Pain, Nerve. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to examine non-invasive pulsed radiofrequency (NIPRF) and the effect it has on chronic neuropathic pain. Chronic neuropathic pain after peripheral nerve injury most often occurs in the context of post-traumatic or post-surgical pain. It is often treated with nerve blocks, prescription medication, physical therapy, neuromodulation, and surgery. The study team will be examining the efficacy of NIPRF and determining if it would be an appropriate treatment for chronic neuropathic pain after peripheral nerve injury.The Stimpod used in the present study is FDA approved and will be used for on label purposes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Active Treatment

Trials testing the same drug.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06185816.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing